Daiichi Sankyo

This phase 3 study tests a new combination of drugs (datopotamab deruxtecan and pembrolizumab) with or without chemotherapy for people with advanced non-small cell lung cancer who have low PD-L1 levels and have not had prior treatment. The goal is to see if this new approach work…

This early-phase study tests a new drug, DS-1001b, in 47 people with a specific type of brain tumor (glioma) that has an IDH1 mutation and has come back after standard treatments. The main goal is to check the drug's safety and how the body processes it, while also looking for si…

This study compares a new drug, DS-1062a, to the standard chemotherapy docetaxel in about 600 adults with advanced non-small cell lung cancer that has worsened after prior treatment. The main goals are to see if DS-1062a can delay cancer growth or improve survival. Participants r…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) in people with extensive-stage small cell lung cancer that has already been treated with chemotherapy. The goal is to see if the drug can shrink tumors and to find the best dose. About 187 adults will take part in t…

This study tests an experimental drug called quizartinib in children and young adults (ages 1 month to 21 years) with a specific type of leukemia (FLT3-ITD AML) that has returned or not responded to treatment. The drug is given with chemotherapy to see if it can help achieve remi…

This study tests a new drug, DS-8201a, against standard treatments for people with a specific type of advanced breast cancer called HER2-low. The cancer has spread and cannot be removed by surgery. The goal is to see if the new drug can slow down the cancer better than current op…

This study tests a new drug, trastuzumab deruxtecan (T-DXd), against a standard treatment (ramucirumab plus paclitaxel) in 490 adults with HER2-positive stomach or gastro-esophageal junction cancer that worsened after initial therapy. The main goal is to see if T-DXd helps people…

This study tests a new drug, trastuzumab deruxtecan (T-DXd), against an existing drug, trastuzumab emtansine (T-DM1), in people with a high-risk type of breast cancer (HER2-positive) that did not fully respond to initial treatment. About 1,635 adults with residual invasive cancer…

This early-phase study tests a new drug called DS-1055a in about 40 adults with advanced solid tumors (like head and neck, stomach, or lung cancer) that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Participants re…

This phase 3 study tests a new drug, DS-8201a, against an existing treatment, T-DM1, in people with advanced HER2-positive breast cancer that has spread or cannot be removed. About 524 adults who have already tried trastuzumab and taxane will take part. The goal is to see which d…

This study tests a combination of two drugs, trastuzumab deruxtecan and pembrolizumab, in adults with advanced breast or non-small cell lung cancer that has spread. The goal is to find the safest dose and see how well the combo shrinks tumors. About 115 participants will receive …

This early-stage study tests a new drug called HER3-DXd in people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed by surgery. The study includes patients with certain genetic changes (EGFR or KRAS mutations) whose cancer worsened after other …

This study tests a drug called valemetostat tosylate in people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not improved after other treatments. About 155 adults will take the drug and be monitored for tumor shrinkage and side effects. The go…

This study tests an experimental drug called patritumab deruxtecan in people with a specific type of advanced lung cancer (EGFR-mutated NSCLC) that has worsened after standard treatments. About 277 participants will receive the drug to see if it shrinks tumors and how long that e…

This study tracks 721 Chinese adults with diabetic peripheral neuropathic pain to see how safe and effective mirogabalin is in everyday medical practice. Participants must have moderate to severe pain and have not taken mirogabalin before. The main focus is on side effects like d…

This study tracks over 2,500 adults with high cholesterol who are taking bempedoic acid (alone or with ezetimibe) in routine medical care. Researchers want to see how safe the drug is and how it affects heart risk, especially in Asian and Latin American patients. No new treatment…

This study is collecting information from medical records of about 760 people with advanced or metastatic triple-negative breast cancer in Canada, the UK, France, and Spain. The goal is to understand how doctors test for biomarkers, what treatments they use, and how well patients…